{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:37:37Z","timestamp":1772264257674,"version":"3.50.1"},"reference-count":19,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2020,4,30]]},"DOI":"10.5582\/bst.2020.03082","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T18:04:14Z","timestamp":1587492254000},"page":"139-143","source":"Crossref","is-referenced-by-count":38,"title":["Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.5582","volume":"14","author":[{"given":"Kenichiro","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Mano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan."},{"name":"Department of Neurology, Tokyo Metropolitan Geriatric Medical Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsushi","family":"Toda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Verity R, Okell LC, Dorigatti I, <i>et al.<\/i> Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; pii: S1473-3099(20)30243-7."},{"key":"2","unstructured":"2. FDA. Coronavirus (COVID-19) Update: Daily Roundup March 30, 2020. <i>https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-daily-roundup-march-30-2020<\/i> (accessed April 6, 2020)."},{"key":"3","unstructured":"3. EMA. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. EMA\/170590\/2020. <i>https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes_en.pdf<\/i> (accessed April 6, 2020)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14:72-73.","DOI":"10.5582\/bst.2020.01047"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; pii: S0883-9441(20)30390-7.","DOI":"10.1016\/j.jcrc.2020.03.005"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. AlKadi HO. Antimalarial drug toxicity: a review. Chemotherapy. 2007; 53:385-91.","DOI":"10.1159\/000109767"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Anna Bogaczewicz, Tomasz Sob\u00f3w. Psychiatric adverse effects of chloroquine. Psychiatr Psychol Klin. 2017; 17:11-114.","DOI":"10.15557\/PiPK.2017.0012"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004; 27:25-61.","DOI":"10.2165\/00002018-200427010-00003"},{"key":"9","unstructured":"9. U.S. Food &amp; Drug Administration. <i>https:\/\/www.fda.gov<\/i> (accessed April 6, 2020)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yokoyama S, Ieda S, Nagano M, Nakagawa C, Iwase M, Hosomi K, Takada M. Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach. Int J Med Sci. 2020; 17:471-479.","DOI":"10.7150\/ijms.39523"},{"key":"11","unstructured":"11. Michel C, Scosyrev E, Petrin M, Schmouder R. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? Clin Drug Investig. 2017; 37:415-422."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nevin RL, Byrd AM. Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada. Neurol Ther. 2016; 5:69-83.","DOI":"10.1007\/s40120-016-0045-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol. 1999; 47:689-93.","DOI":"10.1046\/j.1365-2125.1999.00957.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13:519-23.","DOI":"10.1002\/pds.1001"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sato K, Mano T, Iwata A, Toda T. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol. 2019; 145:1-9.","DOI":"10.1007\/s11060-019-03273-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Larsen K, Petersen JH, Budtz-J\u00f8rgensen E, Endahl L. Interpreting parameters in the logistic regression model with random effects. Biometrics. 2000; 56:909-914.","DOI":"10.1111\/j.0006-341X.2000.00909.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Casals M, Girabent-Farr\u00e9s M, Carrasco JL. Methodological quality and reporting of generalized linear mixed models in clinical medicine (2000-2012): a systematic review. PLoS One. 2014; 9:e112653.","DOI":"10.1371\/journal.pone.0112653"},{"key":"18","unstructured":"18. Bates D, M\u00e4chler M, Bolker B, Steve Walker S. Fitting linear mixed-effects models using lme4. Journal of Statistical Software. 2015; 67: 1-48. doi: 10.18637\/jss. v067.i01"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Thomas KH, Martin RM, Potokar J, Pirmohamed M, Gunnell D. Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. BMC Pharmacol Toxicol. 2014; 15:54.","DOI":"10.1186\/2050-6511-15-54"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/2\/14_2020.03082\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T19:35:46Z","timestamp":1666380946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/2\/14_2020.03082\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2020.03082","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.10.20061358","asserted-by":"object"}]},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]}}}